The purpose of this study is to evaluate the
safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV
NZ) in North American infants 6 weeks through 12 weeks of age, when
administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and
other recommended routine infant vaccines (RIV).
This study will be divided into 3
1- Primary- From day 1 to day 301
2-Secondary-From day 301 to day 331
Epoch 3-Safety follow up
-From day 331 to study end (day 661) In addition to receiving the study
vaccines, infants will also receive non-study vaccines such as Diphtheria,
tetanus toxoids and acellular pertussis adsorbed vaccine (DTPa, Infanrix) and
Haemophilus influenzae type b Conjugate Vaccine (Hib, Hiberix), to ease the
disruption to the standard infant vaccine schedule caused by participating in
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.